CX3CL1 and diffuse large B-cell lymphoma: Thus, clinical application of new therapeutic agents that target the fractalkine/CX3CR1 axis could be applied in the high risk DLBCL patients with high percentage of PB-CD11b+CX3CR1+ monocytes.